XORTX – Therapeutics for Progressive Kidney Disease
Dr. Allen Davidoff, PhD, CEO of XORTX Therapeutics, a clinical-stage biotechnology company developing promising therapeutics for progressive kidney disease, discusses the company’s lead assets that are designed to reduce uric acid to alleviate genetic autosomal dominant polycystic kidney disease (ADPKD) and COVID-19-related kidney injury. The current approved treatment for ADPKD can cause liver failure among other severe symptoms.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on COVID. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in COVID and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about COVID?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Allen Davidoff, PhD, CEO of XORTX Therapeutics, a clinical-stage biotechnology company developing promising therapeutics for progressive kidney disease, discusses the company’s …
- Key Point: The current approved treatment for ADPKD can cause liver failure among other severe symptoms.
- Key Point: Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX.
- Key Point: Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) appli…
- Key Point: Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp.
Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven phase II studies, and one NDA. Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (seven years) ( Trillium TRIL:NASDAQ) and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



